anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Sex disparities in the association between epicardial adipose tissue volume (EATV) and cardiovascular disease have been reported. The sex-dependent effects of EATV on left atrial (LA) size have not been elucidated.
METHODS: Consecutive 247 subjects (median 65 [interquartile range 57, 75] years; 67% of men) who underwent multi-detector computed tomography without significant coronary artery disease or moderate to severe valvular disease were divided into two groups: patients with sinus rhythm (SR) or atrial fibrillation (AF). Sex differences in the association between the EATV index (EATVI) (mL/m2) and LA volume index (LAVI) in 63 SR (28 men and 35 women) and 184 AF (137 men and 47 women) patients were evaluated using univariate and multivariate regression analyses.
RESULTS: In overall that includes both men and women, the relationship between EATVI and LAVI was not significantly correlated for patients with SR and AF. The relationship between EATVI and LAVI differed between men and women in both SR and AF groups. In SR patients, there was a positive relationship between EATVI and LAVI in men, but not in women. In contrast, in patients with AF, a negative relationship was found between EATVI and LAVI in women, whereas no association was found in men.
CONCLUSIONS: We evaluated sex differences in the association between EATVI and LAVI in patients with either SR or AF, and found a positive relationship in men with SR and a negative relationship in women with AF. This is the first report to evaluate sex differences in the relationship between EATVI and LAVI, suggesting that EAT may play a role, at least in part, in sex differences in the etiology of AF.
Saxidomus purpurata extract (SPE) is a highly consumable seafood worldwide with known health-related benefits. However, there are no reports of its' anti-obesity effect. This study explores the potential of SPE for anti-obesity effects by modulating adipogenesis and lipolysis. SPE reduced intracellular lipid and triglyceride accumulation while increasing free glycerol release in adipocytes. SPE inhibited lipogenesis protein expressions and increased the phosphorylation of hormone-sensitive lipase and Adenosine monophosphate-activated protein kinase (AMPK) to promote lipolysis. In addition, SPE suppressed adipogenesis by downregulating protein expression of key adipogenic markers, peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), and sterol regulatory element-binding protein 1 (SREBP1) via Wnt/β-catenin signaling. SPE augmented the heme oxygenase-1 (HO-1) expression. Thus, pharmacological intervention with Zinc protoporphyrin (ZnPP-HO-1 antagonist) was employed to validate the HO-1 role. The presence of ZnPP increased the lipid accumulation and reduced the free glycerol release. At the molecular level, adipogenic transcription factors (PPARγ, C/EBPα, and SREBP1) expressions were restored in the presence of ZnPP. GC-MS analysis revealed that SPE was comprised of several fatty acids, contributing to its anti-obesity activity. SPE is an effective nutraceutical that can be used to reduce the progression of obesity. HO-1 expression during adipogenesis might be the mechanism of action for the anti-obesity effect of SPE.
Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
This disclosure provides modified B cells which produce heterologous antibodies and co-express cargo proteins. The modified B cells may be stimulated by binding of a cognate antigen to the heterologous antibodies. The B cells may be reduced or eliminated by contacting the heterologous antibody with an anti-idiotypic antibody. Methods of making, and using the modified B cells for prophylaxis and therapy for a variety of conditions are provided. The B cells are modified at an IgH locus, an IgK locus, and combinations thereof. Modified B cells maintain allelic exclusion.
The invention relates to a combined extraction method of Paeonia ostii seed oil and Paeonia ostii seed total flavonoids. The method includes: crushing dry Paeonia ostii seeds, conducting ultrasonic assisted extraction to obtain Paeonia ostii seed primary oil, separating Paeonia ostii seed powder in a petroleum ether suspending solution, drying a petroleum ether solution under reduced pressure, drying degreased Paeonia ostii seed powder, carrying out ultrasonic extraction to obtain Paeonia ostii seed total flavonoids, separating Paeonia ostii seed powder from an ethanol suspending solution, and performing pressure reduced evaporation on an ethanol solution so as to obtain the Paeonia ostii seed total flavonoids. Specifically, petroleum ether or a mixed solvent of petroleum ether and n-hexane is adopted for ultrasonic assisted extraction of the Paeonia ostii seed primary oil, and the ethanol solution is employed for assisting ultrasonic extraction of Paeonia ostii seed total flavonoids. The method is characterized by simultaneous extraction of Paeonia ostii seed oil and Paeonia ostii seed total flavonoids, and the technological process is coherent and compact. The extraction rates of the Paeonia ostii seed oil and the Paeonia ostii seed total flavonoids are high. The extracted Paeonia ostii seed powder has high purity and a good color, and can reach the national standards through simple refining. The Paeonia ostii seed total flavonoids extracted by the method have high activity, strong antioxidant capacity, and good bacteriostatic capacity.
BACKGROUND: Minimal invasive inguinal hernia repair is conducted using among others the laparoscopic transabdominal preperitoneal (TAPP) procedure or the extended totally extraperitoneal (eTEP) approach. Robotic-assisted TAPP (R-TAPP) has recently been introduced as an alternative to laparoscopic TAPP and TEP, and a growing number of robotic-assisted procedures are performed worldwide. The present study was conducted to determine the risk of chronic pain and recurrence associated with the two methods.
METHODS: Three hundred ninety-five patients were retrospectively included in the study and underwent either laparoscopic TAPP (n = 177) or R-TAPP (n = 218). Data on patient demographics, hernia characteristics, and postoperative outcomes were retrieved from medical records. Kaplan-Meier curves and Cox proportional hazards regression were used to assess hernia recurrence. Logistic regression was used to analyze secondary outcomes such as inpatient status, hematoma, and chronic pain.
RESULTS: The Kaplan-Meier curves indicated a consistently higher cumulative incidence of recurrence in the TAPP group compared to the R-TAPP. Consistent with this finding, the Cox regression showed a higher risk of recurrence in patients undergoing TAPP, with a hazard ratio (HR) of 3.489 (95% CI: 1.232 to 9.880, p = 0.019). The E-value for this HR was 6.44, suggesting robustness to unmeasured confounding. There was no difference in the rates of chronic pain between the groups (OR: 1.233, 95% CI: 0.430 to 3.533, p = 0.696). A logistic regression analysis for other postoperative complications revealed no significant differences.
CONCLUSION: This study provides evidence that robotic-assisted TAPP is associated with a lower risk of recurrence than laparoscopic TAPP.
Ayres Sensory Integration (ASI) therapy will be applied to children in the intervention group. In the intervention group, Ayres Sensory Integration Therapy will be performed 3 days a week for a total of 10 weeks, 60 minutes each session, in accordance with the Ayres Sensory Integration Fidelity Measure (ASI-FM). A manualized protocol will be followed based on the principles of ASI-FM, Ayres sensory integration.
A potential mechanism of bleeding in patients with continuous-flow left ventricular assist devices (CF-LVAD) is dysfunctional angiogenesis. Angiogenesis is a complicated process controlled by several markers. Previous studies have shown that elevated Angiopoietin-2 and TNF-alpha are associated with bleeding events in CF-LVAD patients.

Fish oil has anti-inflammatory and potentially anti-angiogenic properties. A retrospective study of CF-LVAD patients on high-dose fish oil showed a marked decrease in gastrointestinal bleeding rates in these patients. Additionally, these patients had lower levels of circulating Angiopoietin-2. Fish oil is known to have an effect on the microbiome, and the aforementioned effects may be seen in changes of the microbiota.
Among the complications of postoperative recovery from proximal humerus fractures (PHF) are pain and joint stiffness, which can significantly limit limb function. Physical therapy is standard for both surgical and non-surgical treatments. Research suggests that photobiomodulation (PBM) positively affects fracture repair, regeneration, analgesia, and functional improvement, but more standardization and evidence are needed. This double-blind, randomized controlled study aims to assess PBM's impact on functional recovery in patients with surgically treated PHF using specialized locking plates. Forty-two participants will be randomly assigned (1:1) to either the Control group (standard physiotherapy with simulated PBM) or the FBM group (standard physiotherapy with active PBM). The PBM will be administered at home daily for 10 minutes using a device with 318 LEDs: 159 at 660 nm (28.5 mW; 12 J/cm²; 17 J per LED) and 159 at 850 nm (23 mW; 10 J/cm²; 14 J per LED). PBM and physiotherapy sessions (30 minutes, twice a week) will continue for 12 weeks. Participants and examiners will be blinded to group allocation. The primary outcome is shoulder function recovery, measured by the Quick-DASH scale, that will be evaluated 1, 2, 4, 8, and 12 weeks after surgery . Secondary outcomes include shoulder range of motion (digital goniometer), quality of life (SF-6 questionnaire), and adverse effects. The intensity of spontaneous pain and pain during movement of the injured limb will be assessed using the visual analog scale for pain. Pressure pain at the fracture site will be evaluated with a digital algometer (MED DOR, Governador Valadares, MG, Brazil) at 1, 2, 4, 8, and 12 weeks. Fracture consolidation via radiographs at 4, 8, and 12 weeks, and muscle strength through progressive weight bearing at 8 and 12 weeks. Data will be stored, organized, and analyzed using appropriate statistical tests, with a significance level set at 5%.

Keywords: Photobiomodulation, Humerus Fracture, Quick-DASH, Quality of life, Phototherapy
BACKGROUND: Knowledge on hearing aid use and benefit is important to ensure appropriate and effective treatment. We aimed to assess prevalence and predictors of hearing aid use and benefit in Norway, as well as possible birth cohort changes.
METHODS: We analyzed two large cross-sectional, population-based hearing surveys of 63,182 adults in 1996-1998 and 2017-2019 (the HUNT study). We used multivariable regression models to examine independent predictors of hearing aid use and benefit, including demography, hearing-related variables, known risk factors for hearing loss and birth cohort.
RESULTS: The nationally weighted hearing aid use in the adult population increased from 4.2% in 1997 to 5.8% in 2018. The use among individuals with disabling hearing loss (≥ 35 dB HL) increased from 46.3% to 64.4%. Most users reported some (47%) or great (48%) help from their hearing aids. In addition to the level of hearing loss and birth cohort, factors associated with hearing aid use included lower age, tinnitus, childhood-onset hearing loss, higher education, marriage, having children, being exposed to occupational noise or impulse noise, recurrent ear infections, and head injury. In addition to the level of hearing loss, factors related to hearing aid benefit included younger age, female gender, and higher income. Being bothered by tinnitus reduced the benefit.
CONCLUSION: Our study shows an increase in self-reported hearing aid usage over time in Norway, with lower adoption rates and perceived benefits observed among the elderly. The results suggest that having a spouse and children positively influences the adoption of hearing aids. These findings emphasize the necessity of customized strategies to address demographic disparities and the need for innovative enhancements in hearing rehabilitation programs.
Heart failure (HF) is a clinical syndrome of exercise intolerance and/or congestion. The management of heart failure with reduced ejection fraction (HFrEF) has improved over the last decades. In contrast, little progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HFpEF, LVEF \>50%). Treatments proven effective in HFrEF have failed to show significant benefit in patients with HFpEF. Potential contributors include an incomplete understanding of pathophysiology and poor matching of therapeutic mechanisms. The challenges of the use of diagnostic criteria, prognostic evaluation and treatment highlight the need for more research in this field.

This portion of HFpEF consists predominantly older age and high prevalence of co-morbidity such as overweight/obesity, diabetes mellitus, hyperlipidemia, metabolic syndrome and hypertension. The systemic pro-inflammatory state may induce coronary endothelial inflammation, microvasular dysfunction, myocardial substrate shift, myocardial and interstitial fibrosis that contribute to high diastolic left ventricular stiffness and HF development. Myocardial metabolic and perfusion imaging is a vital tool for understanding the physiologic consequences of HF. Absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) provide incremental diagnostic and prognostic information over relative perfusion alone. Recent development of dedicated cardiac SPECT cameras with better sensitivity and temporal resolution make dynamic SPECT imaging more practical. Quantitative 18F-FDG PET could be used as a means to measure myocardial metabolic changes. The study investigators propose that microvasular dysfunction and abnormal metabolic substrate shift precedes and triggers the onset of diastolic dysfunctions. The potential roles of myocardial perfusion and metabolic abnormalities in subjects with cardiovascular risks, metabolic disease and HFpEF assessed by nuclear dynamic imaging warrant further investigations.

The present project aims (1) to develop and validate the noninvasive measurement of absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) by using dynamic imaging with a CZT camera, (2) to assess myocardial glucose metabolism by using 18F-FDG dynamic PET, and MBF, MFR and LV systolic and diastolic function by dynamic SPECT comprehensively in participants at cardiovascular risks and metabolic disease, HFrEF and HFpEF, (3) to correlate with peripheral serum markers and blood mononuclear cells subsets with myocardial perfusion and metabolic abnormalities, and (4) to test the hypothesis of these imaging and blood markers in diagnosis and prognostic implications. The study investigators also assess myocardial metabolic utilization in healthy and mice model of different metabolic disorders (obesity, diabetes mellitus and hypertension) by using 18F-FDG dynamic micro PET/CT, as an in-vivo measures which could be used to better understanding the disease mechanism and evaluating therapeutic strategies.
PURPOSE:To obtain a stable perfumery composition effective in preventing the decomposition of a monoterpene compound with light and heat, by compounding a monoterpene compound with a specific hydroxybenzophenone derivative. CONSTITUTION:The objective perfumery composition is produced by compounding a monoterpene compound such as limonene, alpha-pinene, lemon oil, etc., with a hydroxybenzophenone derivative of formula (R1 and R2 are H, OH or alkoxy) (e.g. dihydroxybenzophenone, tetrahydroxybenzophenone, etc.). The amounts of the monoterpene compound and the hydroxybenzophenone derivative are preferably 0.05-15wt% and 0.01-3wt%, respectively. EFFECT:The composition can be stably stored over a long period. USE:Perfumery, face lotion, etc.
A substance delivery device includes a substrate, a plurality of soluble supporting structures and a plurality of carriers. The substrate attaches a tissue. The soluble supporting structures are disposed on the substrate. The carriers are disposed on the soluble supporting structures and covering substances. The present invention further provides a substance delivery method. The substance delivery device and the substance delivery method of present invention is advantageous for providing sustained release effect and rising the applicability of transdermal or transmucosal delivery techniques.
The invention discloses a drug used for treating gout. The drug comprises, by weight, 60g of shark cartilage, 90g of cortex eucommiae, and 90g of radix achyranthis bidentatae. A preparation method comprises following steps: 60g of shark cartilage is baked and grinded, is divided into 12 parts, and is packaged; one part of the processed shark cartilage is taken in two times each day; cortex eucommiae and radix achyranthis bidentatae are fried with salt water, and are decocted with water so as to obtain a decoction, and the obtained decoction is divided into 24 parts. The processed shark cartilage is taken together with the decoction. Cortex eucommiae is sweet in taste, slightly pungent, and warm in nature, belongs to liver and kidney channel, is capable of harmonizing gas and reducing moisture, nourishing liver and kidney, strengthening bones and muscles, and preventing miscarriage, and is mainly used for treating waist and knee pain, erectile dysfunction, spermatorrhea, frequent micturition, long lasting urinating, yang-hyperactivity and arthralgia spasm pain, rheumatic arthralgia, pruritus vulvae, threatened abortion, miscarriage and abortion. Radix achyranthis bidentatae is sweet, bitter, and sour in taste, and is neutral in nature; raw radix achyranthis bidentatae is capable of dispersing blood stasis, and relieving carbuncle swollen, and is mainly used for treating gonorrhea, hematuria, amenorrhea, abdominal mass, dystocia, placenta retension, postpartum blood stasis and stomachache, pharyngitis, carbuncle swollen, injuries from falls, fractures, contusions and strains; and processed radix achyranthis bidentatae is capable of nourishing liver and kidney, and strengthening bones and muscles, and is mainly used for treating waist knee bone pain, arms and legs contracture, and atrophy and flaccidity.
The first treatment group will be given aerobic exercises for six weeks at least three times per week. This group will include 14 participants. This study group will be assigned with basic treatment protocol with aerobic exercises along with 10 minutes of warm up period.
The present invention relates to a pharmaceutical composition for treating and preventing stroke and thrombus and, more specifically, to a pharmaceutical composition for treating and preventing stroke and thrombus, which is produced by medicinal herbs of ginger extract, pinellia, cinnamomi ramulus, paeonia japonica, atractylodes rhizome alba, citrus unshiu, aurantii fructus, citri reticulatae viride pericarpium, lindera strichnifolia Fernandez-Villar, arisaema amurense var. serratum, mucunae caulis, roasted glycyrrhiza uralensis FISCH, etc, wherein the materials have excellent pharmacological effects for stroke and thrombus. A pharmaceutical composition containing herbal extracts for treating and preventing stroke and thrombus according to the present invention is produced by extracting a mixture of ginger extract, pinellia, Cinnamomi Ramulus, Paeonia japonica, Atractylodes Rhizome Alba, Citrus unshiu, Aurantii Fructus, Citri reticulatae viride pericarpium, lindera strichnifolia Fernandez-Villar, Arisaema amurense var. serratum, Mucunae caulis, roasted Glycyrrhiza uralensis FISCH. The pharmaceutical composition for treating and preventing stroke and thrombus according to the present invention is manufactured by mixing 16 parts by weight of of ginger extract, 2 parts by weight of pinellia, 2 parts by weight of Cinnamomi Ramulus, 1 parts by weight of Paeonia japonica, 1 parts by weight of Atractylodes Rhizome alba, 1 parts by weight of Citrus unshiu, 1 parts by weight of Aurantii Fructus, 1 parts by weight of Citri reticulatae viride pericarpium, 1 parts by weight of lindera strichnifolia Fernandez-Villar, 1 parts by weight of Arisaema amurense var. serratum, 1 parts by weight of roasted Glycyrrhiza uralensis FISCH, 5 parts by weight of Mucunae Caulis at the mixing ratio.
PROBLEM TO BE SOLVED: To obtain an adhesive consisting of a specific adhering component, a polymerizable monomer capable of copolymerizing the adhering component and a polymerization initiator, having an excellent adhesion to a metal, especially to a precious metal and suitably used in the field of dentistry. SOLUTION: This adhesive contains (A) a compound having mercapto group or a polysulfide group bound with a saturated carbon and also an olefinic double bond, (B) a polymerizable monomer having a copolymerizing property with the component (A) [suitably, a (meth)acrylic acid ester such as methylmethacrylate] and (C) a polymerization initiator (e.g.; cumenehydroperoxide). As the component (A), a thiol compound of the formula [R1 is H or methyl; R2 is a 1-40C organic group; R3 , R4 are each H, mercapto, etc.; X is COO, S, etc.; (1) is 0, 1] is preferable. It is preferable to prepare the adhesive by using a method of dissolving the component (A) with the component (B) so as to make 0.005-50wt.% concentration thereof based on the total of the components (A) and (B), and further adding the component (C).
Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
Participants will receive placebo matching to GLPG3667 orally once daily for 24 weeks in the DB treatment period. Eligible participants will roll-over to an OLE period to receive GLPG3667 dose A orally once daily for another 24 weeks.
FIELD: medicine. SUBSTANCE: method involves examining blood in process of applying physical loading to determine phagocytic activity of neutrophils according to Right method. Lack of training is considered to take place, if index value being equal to 0.5-1.5. The index value being equal to 1.6-1.5, trained state is considered to take place. Contact transducer is mounted in shoes of sportsmen. Piezoelectric transducer is fixed on one of the sportsman wrists to form a series of rectangular pulses for modulating amplitude and phase of high frequency oscillations which are transmitted into the ether to be received demodulated, recorded later with the aim to estimate speed at which sportsmen move, their pulse rates, skill in overcoming distance and uniformity of power distribution over the whole distance. The miniature emitters are mounted on the sportsmen and receivers are mounted at start place. EFFECT: enhanced effectiveness medical examination of sportsmen. 1 tbl